A review of pulmonary arterial hypertension: role of ambrisentan
Robyn J BarstColumbia University College of Physicians & Surgeons, New York, NY, USAAbstract: Pulmonary arterial hypertension (PAH) is a rare fatal disease. Current disease-specific therapeutic interventions in PAH target 1 of 3 established pathways in disease pathobiology: prostacyclin, nit...
Main Author: | Robyn J Barst |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2007-03-01
|
Series: | Vascular Health and Risk Management |
Online Access: | https://www.dovepress.com/a-review-of-pulmonary-arterial-hypertension-role-of-ambrisentan-peer-reviewed-article-VHRM |
Similar Items
-
Ambrisentan for the treatment of pulmonary arterial hypertension
by: Brian Casserly, et al.
Published: (2008-12-01) -
Ambrisentan: a review of its use in pulmonary arterial hypertension
by: Belinda N. Rivera-Lebron, et al.
Published: (2017-06-01) -
Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
by: Elshaboury SM, et al.
Published: (2013-05-01) -
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension
by: Buendia, JA, et al.
Published: (2023) -
Pulmonary arterial hypertension : diagnosis and evidence-based treatment /
by: Barst, Robyn
Published: (2008)